2023
Performance of a modified fracture risk assessment tool for fragility fracture prediction among older veterans living with HIV
Womack J, Murphy T, Leo-Summers L, Kidwai-Khan F, Skanderson M, Gill T, Gulanski B, Rodriguez-Barradas M, Tien P, Yin M, Hsieh E. Performance of a modified fracture risk assessment tool for fragility fracture prediction among older veterans living with HIV. AIDS 2023, 37: 1399-1407. PMID: 37070536, PMCID: PMC10329997, DOI: 10.1097/qad.0000000000003566.Peer-Reviewed Original ResearchConceptsFracture Risk Assessment ToolMajor osteoporotic fractureRisk assessment toolCohort studyHip fractureOsteoporotic fracturesVeterans Aging Cohort StudyAging Cohort StudyMultivariable logistic regressionType of fractureRace/ethnicityAssessment toolGlucocorticoid useHIV cohortFragility fracturesPrevious fractureRheumatoid arthritisSmoking statusFracture riskModest discriminationOlder veteransLogistic regressionOccurrence of fracturesHIVAlcohol use
2022
Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations
Jin S, Jiang N, Huo Y, Duan X, Fang Y, Zhao C, Li H, Yang M, Huang Z, Yang P, Zhang H, Zhan F, Wang Y, Wang Y, Wu C, Wang Q, Hsieh E, Li M, Tian X, Zhao Y, Zeng X. Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations. Annals Of The Rheumatic Diseases 2022, 81: 1052-1054. PMID: 35168947, DOI: 10.1136/annrheumdis-2021-221841.Peer-Reviewed Original Research
2021
Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment
Hanberg JS, Hsieh E, Akgün KM, Weinstein E, Fraenkel L, Justice AC, Team T. Incident Rheumatoid Arthritis in HIV Infection: Epidemiology and Treatment. Arthritis & Rheumatology 2021, 73: 2189-2199. PMID: 34042306, DOI: 10.1002/art.41802.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsIncident rheumatoid arthritisDiagnosis of RARA patientsRheumatoid arthritisRheumatoid factorUninfected individualsRheumatology/European AllianceHigh titersVeterans Aging Cohort StudyRA-specific autoantibodiesRheumatology 2010 criteriaTenth Revision codesAging Cohort StudyIncidence rate ratiosHigh autoantibody titersICD-10 codesDMARD useUninfected veteransAntirheumatic drugsAutoantibody titersCohort studyImmunosuppressed populationHIV infectionMedical chartsEarly experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui SE, Liew JW, Kennedy K, Sirotich E, Putman M, Moni TT, Akpabio A, Alpízar-Rodríguez D, Berenbaum F, Bulina I, Conway R, Singh AD, Duff E, Durrant KL, Gheita TA, Hill CL, Howard RA, Hoyer BF, Hsieh E, Kibbi L, Kilian A, Kim AH, Liew DFL, Lo C, Miller B, Mingolla S, Nudel M, Palmerlee CA, Singh JA, Singh N, Ugarte-Gil MF, Wallace J, Young KJ, Bhana S, Costello W, Grainger R, Machado PM, Robinson PC, Sufka P, Wallace ZS, Yazdany J, Harrison C, Larché M, Levine M, Foster G, Thabane L, Rider LG, Hausmann JS, Simard JF, Sparks JA. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021, 7: e001814. PMID: 34493645, PMCID: PMC8424419, DOI: 10.1136/rmdopen-2021-001814.Peer-Reviewed Original ResearchConceptsDisease-modifying antirheumatic drugsPatient-reported adverse eventsSystemic rheumatic diseasesCOVID-19 vaccinationRheumatic disease flareRheumatic diseasesDisease flareCOVID-19 vaccineAdverse eventsVaccine efficacyMuscle/joint painJanssen/JohnsonTime of vaccinationFever/chillsCommon rheumatic diseasePatient-reported dataOxford/AstraZenecaEarly experienceVaccines surveyAntirheumatic drugsMedication changesJoint painMost patientsPfizer-BioNTechRheumatoid arthritisBone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT
Jin S, Li M, Wang Q, Zeng X, Xia W, Yu W, Guan W, Hsieh E. Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis: a cross-sectional study with HRpQCT. Arthritis Research & Therapy 2021, 23: 127. PMID: 33894786, PMCID: PMC8067377, DOI: 10.1186/s13075-021-02503-0.Peer-Reviewed Original ResearchConceptsBone mineral densityRheumatoid arthritisRisk of fractureCross-sectional studyMineral densityFragility fracturesDistal radiusHealthy controlsBone microarchitectureBone strengthHigh-resolution peripheral quantitative computed tomographySex-matched healthy controlsPeripheral quantitative computed tomographyDual-energy X-ray absorptiometryVolumetric bone mineral densityFemale reproductive factorsRA-related characteristicsThoracolumbar X-rayTraditional risk factorsQuantitative computed tomographyX-ray absorptiometryCortical bone thicknessThin cortical boneGroup of ageChinese Registry
2020
Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target
Xiang Y, Wang Q, Li H, Duan X, Fang Y, Yang P, Li Q, Wu R, Huo Y, Shi X, Wu Z, Wang Y, Jiang N, Hsieh E, Li M, Tian X, Zeng X, co‐authors C. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target. International Journal Of Rheumatic Diseases 2020, 23: 1719-1727. PMID: 33034424, DOI: 10.1111/1756-185x.13996.Peer-Reviewed Original ResearchConceptsBiologic disease-modifying anti-rheumatic drugsDisease activityTreatment responseChinese RegistryRheumatoid arthritisDisease-modifying anti-rheumatic drugsBaseline Disease Activity ScoreConventional DMARD therapyLower baseline DAS28Baseline disease activityDisease Activity ScoreAnti-rheumatic drugsBaseline DAS28DMARD therapyLDA ratesPrednisolone usageSynthetic DMARDsEarly RADisease durationActivity scoreTreatment strategiesTreatment targetsYounger agePatientsBaseline